Altimmune, Inc. (ALT)
NASDAQ: ALT · Real-Time Price · USD
6.18
+0.52 (9.19%)
At close: Jan 27, 2026, 4:00 PM EST
5.47
-0.71 (-11.49%)
Pre-market: Jan 28, 2026, 7:34 AM EST
Altimmune Revenue
Altimmune had revenue of $5.00K in the quarter ending September 30, 2025. This brings the company's revenue in the last twelve months to $20.00K, down -61.54% year-over-year. In the year 2024, Altimmune had annual revenue of $20.00K, down -95.31%.
Revenue (ttm)
$20.00K
Revenue Growth
-61.54%
P/S Ratio
33,728.90
Revenue / Employee
$339
Employees
59
Market Cap
674.58M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 20.00K | -406.00K | -95.31% |
| Dec 31, 2023 | 426.00K | 494.00K | - |
| Dec 31, 2022 | -68.00K | -4.48M | - |
| Dec 31, 2021 | 4.41M | -3.78M | -46.12% |
| Dec 31, 2020 | 8.19M | 2.38M | 41.09% |
| Dec 31, 2019 | 5.80M | -4.53M | -43.85% |
| Dec 31, 2018 | 10.33M | -407.15K | -3.79% |
| Dec 31, 2017 | 10.74M | 7.50M | 231.82% |
| Dec 31, 2016 | 3.24M | -7.40M | -69.59% |
| Dec 31, 2015 | 10.64M | 450.46K | 4.42% |
| Dec 31, 2014 | 10.19M | -7.72M | -43.11% |
| Dec 31, 2013 | 17.91M | -7.26M | -28.85% |
| Dec 31, 2012 | 25.18M | 909.61K | 3.75% |
| Dec 31, 2011 | 24.27M | 3.27M | 15.59% |
| Dec 31, 2010 | 20.99M | -6.56M | -23.80% |
| Dec 31, 2009 | 27.55M | -5.36M | -16.29% |
| Dec 31, 2008 | 32.91M | 18.27M | 124.75% |
| Dec 31, 2007 | 14.64M | 12.98M | 780.39% |
| Dec 31, 2006 | 1.66M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Rigel Pharmaceuticals | 282.08M |
| REGENXBIO | 161.32M |
| Gyre Therapeutics | 107.27M |
| Fulcrum Therapeutics | 80.00M |
| Lexicon Pharmaceuticals | 70.86M |
| MeiraGTx Holdings | 27.42M |
| Evommune | 13.00M |
| ProKidney | 744.00K |
ALT News
- 10 hours ago - Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common Stock - GlobeNewsWire
- 23 days ago - Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH - GlobeNewsWire
- 5 weeks ago - Altimmune: Pemvidutide's 48-Week Data Confirms The Market's Smokescreen - Seeking Alpha
- 5 weeks ago - Altimmune's MASH Drug Shows Durable Liver, Weight Loss Gains At 48 Weeks - Benzinga
- 5 weeks ago - Altimmune, Inc. (ALT) Discusses Topline 48-Week Results From IMPACT Phase IIb Trial of Pemvidutide in MASH Transcript - Seeking Alpha
- 5 weeks ago - Altimmune's drug for a type of liver disease shows benefits in mid-stage study - Reuters
- 5 weeks ago - Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial - GlobeNewsWire
- 2 months ago - Altimmune Announces CEO Transition and Succession Plan - GlobeNewsWire